Cognito Therapeutics

Cognito is developing novel and innovative therapeutics designed to potentially improve the lives of patients living with neurodegenerative disease. For decades, neurobiologists have been aware that undisrupted gamma wave activity is a measure of brain health and supports key brain processes involved in synaptic and myelin plasticity. Furthermore, this activity is disrupted in neurodegenerative conditions such as Alzheimer’s disease. During preclinical research at MIT, Ed Boyden and Li-Huei Tsai pushed this knowledge further. They hypothesized that sensory stimulation could evoke gamma activity in Alzheimer’s disease to slow the rate of disease progression. After confirming these observations in preclinical models, they founded Cognito to bring this breakthrough to patients

—

Learn more at: cognitotx.com